"How does radiation therapy work in cancer treatment?"

Linear accelerator positioned over a clinical treatment table in a teal-lit oncology suite, highlighting the machine's curved arm and precise engineering.

Radiation therapy works by delivering high-energy radiation to a targeted area of the body, damaging the DNA inside cancer cells so they can no longer divide and grow. The treatment exploits a key biological difference between cancer cells and healthy tissue: cancer cells are less able to repair radiation-induced DNA damage, making them more vulnerable to its effects. The sections below unpack the mechanisms, delivery methods, treatment schedules, and research context behind modern radiotherapy.

What types of cancer are treated with radiation therapy?

Radiation therapy is used across a wide range of cancer types, including breast, prostate, lung, head and neck, cervical, and brain cancers. It can be applied as a primary treatment, as an adjunct to surgery or chemotherapy, or as palliative care to reduce tumor-related symptoms. Its suitability depends on tumor location, size, stage, and the patient’s overall health profile.

In research settings, radiotherapy is being investigated for an expanding number of indications. Advances in imaging and dose delivery have made it possible to target tumors with greater precision, which has opened the door to treating lesions that were previously considered too close to critical structures. Radiation oncology research in 2026 continues to explore combinations with immunotherapy, targeted agents, and novel sensitizing compounds that may broaden the range of tumor types where radiotherapy can contribute to treatment strategies.

How does radiation damage cancer cells at the molecular level?

Radiation damages cancer cells primarily by inducing double-strand breaks in DNA. When both strands of the DNA helix are severed simultaneously, the cell loses its ability to replicate accurately. Cancer cells, which divide rapidly and often have compromised DNA repair pathways, accumulate this damage and are directed toward programmed cell death, or apoptosis.

At the molecular level, ionizing radiation generates free radicals, particularly reactive oxygen species, within the cell. These unstable molecules attack DNA directly and also damage proteins and lipid membranes. Normal cells retain more robust repair machinery, which allows them to recover between treatment sessions. Cancer cells, by contrast, are less efficient at executing these repairs, which is the biological rationale behind fractionated dosing schedules.

Research into the radiobiology of different tumor types has revealed that not all cancers respond identically to radiation. Factors such as tumor hypoxia (low oxygen levels), cell cycle phase, and the presence of specific genetic mutations all influence how effectively radiation can disrupt cancer cell replication. Understanding these variables is an active area of laboratory investigation, including work conducted in preclinical models such as organoid systems and advanced cell culture platforms.

What is the difference between external beam radiation and brachytherapy?

External beam radiation therapy (EBRT) delivers radiation from a machine positioned outside the body, directing beams toward the tumor from multiple angles. Brachytherapy, by contrast, places radioactive sources directly inside or immediately adjacent to the tumor. The key distinction is proximity: brachytherapy delivers a high local dose while limiting exposure to surrounding tissue.

External beam radiation therapy

EBRT is the most widely used form of radiotherapy. Modern techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) allow clinicians to shape dose distributions with high precision, conforming the radiation field closely to the tumor volume. Image guidance systems are routinely used to verify patient positioning before each session, minimizing the margin of error.

Brachytherapy

Brachytherapy is commonly used in prostate, cervical, and breast cancers, among others. Radioactive seeds or wires are implanted temporarily or permanently, delivering a concentrated dose over a short distance. Because the radiation intensity falls off rapidly with distance, healthy tissue just beyond the implant receives comparatively little exposure. Research into new isotopes and applicator designs continues to refine the dosimetric profiles achievable with this approach.

Why is radiation therapy given in multiple sessions instead of one dose?

Radiation therapy is divided into multiple sessions, called fractions, because this schedule exploits biological differences between cancer cells and healthy tissue. Delivering the total dose in smaller increments over days or weeks allows normal cells to repair between sessions, while cancer cells accumulate irreparable damage. This principle, known as fractionation, is one of the foundational concepts in radiation oncology.

The rationale draws on four key radiobiological principles, often summarized as the “four Rs”:

  1. Repair: Normal cells repair sublethal DNA damage between fractions; cancer cells do so less effectively.
  2. Redistribution: Fractionation catches cancer cells in different, more radiosensitive phases of the cell cycle across sessions.
  3. Repopulation: Spreading treatment over time limits the window during which surviving tumor cells can repopulate.
  4. Reoxygenation: Hypoxic tumor cells, which are more resistant to radiation, become better oxygenated as the tumor shrinks between fractions, increasing their radiosensitivity.

Hypofractionation, which uses fewer but larger doses per session, is an active area of clinical research. Stereotactic approaches deliver very high doses in just one to five fractions, and research is ongoing to identify which tumor types and patient profiles are best suited to these compressed schedules.

What are the most common side effects of radiation therapy?

The most common side effects of radiation therapy are fatigue and localized skin reactions in the treated area. Other effects depend heavily on the anatomical site being irradiated and the total dose delivered. Side effects are generally categorized as acute, occurring during or shortly after treatment, and late effects, which may develop months to years afterward.

Common acute side effects include:

  • Fatigue, which is among the most frequently reported symptoms across all treatment sites
  • Skin redness, dryness, or peeling in the radiation field
  • Mucositis or difficulty swallowing when the head and neck area is treated
  • Nausea or digestive changes when the abdomen or pelvis is in the treatment field
  • Hair loss restricted to the irradiated area

Late effects are generally related to fibrosis or changes in blood vessel integrity in the treated tissue. Research into radioprotective agents and optimized dose delivery continues to focus on reducing the burden of both acute and late toxicities without compromising the intended effect on tumor tissue.

How is radiation therapy combined with surgery or chemotherapy?

Radiation therapy is frequently combined with surgery or chemotherapy because each modality targets cancer through a different mechanism, and their effects can be complementary. Used together, these approaches may address different aspects of tumor biology that no single treatment could handle as effectively in isolation. The sequencing and combination strategy depend on tumor type, stage, and the specific goals of the treatment plan.

When combined with surgery, radiation can be administered before the procedure (neoadjuvant) to reduce tumor volume, or after it (adjuvant) to address residual microscopic disease. Intraoperative radiation therapy, delivered directly to the surgical site during the procedure itself, is a more specialized approach under continued investigation.

Chemotherapy and radiation are often given concurrently because certain chemotherapy agents act as radiosensitizers, making cancer cells more vulnerable to radiation-induced DNA damage. This combination is a well-established research area in oncology, with ongoing studies examining which molecular targets and drug classes produce the most meaningful sensitization effects in specific tumor types.

Immunotherapy combined with radiotherapy is a rapidly evolving area of research. The hypothesis driving much of this work is that radiation-induced tumor cell death may release antigens that stimulate an immune response, potentially amplifying the effect beyond the irradiated field. This phenomenon, sometimes called the abscopal effect, is being actively studied in preclinical and early-phase research settings across the Benelux and internationally.

How BioSPX supports radiation oncology research

Understanding the cellular and molecular mechanisms of radiotherapy depends on robust laboratory tools. Research teams in the Benelux investigating radiation biology, tumor models, and combination therapy strategies rely on precise, reliable instrumentation to generate reproducible results.

BioSPX supports life science researchers across Belgium, the Netherlands, and Luxembourg with instruments and expertise relevant to radiation oncology research, including:

  • Multimode readers and imaging systems for assessing cell viability, DNA damage markers, and apoptosis assays
  • Liquid handling solutions for high-throughput screening of radiosensitizing compounds
  • Cell culture automation platforms, including organoid-compatible systems, for building and maintaining the tumor models used in radiobiology studies
  • Expert product specialists who advise on experimental setup and instrument configuration for specific research workflows
  • Installation, training, and rapid maintenance support from a dedicated service team

If you are setting up or scaling a radiation biology research workflow in the Benelux, contact BioSPX to discuss which instruments and configurations best fit your research goals.

Frequently Asked Questions

How do radiation oncologists determine the right dose for each patient?

Radiation dose is determined through a process called treatment planning, where a multidisciplinary team uses detailed imaging (typically CT, MRI, or PET scans) to map the tumor and surrounding critical structures. Dosimetrists and radiation oncologists use specialized software to calculate a dose distribution that maximizes coverage of the tumor while keeping exposure to healthy organs within established tolerance limits. Factors such as tumor type, stage, prior treatments, and the patient’s overall health all influence the final prescription. The plan is reviewed and approved before the first treatment session begins.

What is the difference between radiosensitive and radioresistant tumors, and does it affect treatment outcomes?

Radiosensitive tumors, such as lymphomas and seminomas, respond readily to radiation-induced DNA damage and often achieve high local control rates with standard doses. Radioresistant tumors, including certain sarcomas and glioblastomas, have more effective DNA repair mechanisms, higher proportions of hypoxic cells, or other biological features that reduce radiation’s impact. This distinction directly influences treatment planning: radioresistant tumors may require higher doses, altered fractionation schedules, or combination strategies with radiosensitizing agents. Ongoing research into tumor-specific biomarkers aims to predict radiosensitivity before treatment begins, enabling more personalized approaches.

Can radiation therapy be repeated if a tumor recurs in the same area?

Re-irradiation is possible in some cases but requires careful consideration, because tissues have cumulative dose tolerances and prior radiation may have already brought nearby healthy structures close to their limits. Advances in highly conformal techniques such as SBRT and proton therapy have made re-irradiation more feasible by delivering precise doses that minimize additional exposure to previously treated tissue. The decision depends on the time elapsed since the original treatment, the dose already delivered, the location of the recurrence, and the patient’s overall condition. A radiation oncologist will weigh these factors individually before recommending this approach.

What is proton therapy, and how does it differ from conventional photon-based radiation?

Proton therapy uses protons rather than X-rays (photons) to deliver radiation. The key physical advantage is the Bragg peak: protons deposit the majority of their energy at a precise, controllable depth within tissue, then stop, releasing very little exit dose beyond the tumor. Conventional photon beams, by contrast, continue to deposit energy as they pass through the body. This property makes proton therapy particularly valuable for tumors near critical structures, such as pediatric brain tumors or skull base cancers, where minimizing collateral dose is a priority. However, proton therapy requires specialized and costly infrastructure, which limits its current availability.

How are late side effects of radiation therapy monitored and managed after treatment ends?

Patients who have completed radiation therapy typically enter a structured follow-up program with their oncology team, with the frequency and content of visits tailored to the treatment site and individual risk profile. Late effects such as fibrosis, lymphedema, hormonal changes, or secondary malignancy risk are screened for at regular intervals, often for years after treatment. Management strategies range from physiotherapy and pharmacological interventions to surgical correction in more severe cases. Early reporting of new or changing symptoms is encouraged, as many late effects are more manageable when identified and addressed promptly.

What role does tumor oxygenation play in radiation response, and is it something researchers can target?

Oxygen is a potent radiosensitizer: it reacts with radiation-induced free radicals to form stable DNA-damaging compounds, amplifying the lethal effect on cancer cells. Hypoxic tumor regions, which are common in solid tumors due to abnormal or insufficient blood vessel growth, are significantly more resistant to radiation. This is one of the reasons fractionated schedules improve outcomes, as reoxygenation occurs between sessions. Researchers are actively investigating strategies to overcome hypoxia, including hypoxic cell sensitizers, hyperbaric oxygen, and vascular-targeting agents, and preclinical models that replicate tumor oxygen gradients are an important tool in this work.

What should a research team consider when setting up an in vitro radiation biology workflow in the lab?

A robust in vitro radiation biology workflow requires careful attention to cell model selection, irradiation conditions, and the assays used to quantify biological endpoints. Researchers should ensure their cell culture models (whether standard 2D cultures, 3D spheroids, or organoids) reflect the tumor biology they aim to study, as radiation responses can differ significantly between model systems. Standardizing irradiation parameters, including dose rate, energy, and timing relative to treatment, is critical for reproducibility. Downstream assays for DNA damage (such as γ-H2AX foci quantification), cell viability, and apoptosis require well-calibrated detection instruments and, ideally, automated liquid handling to reduce variability across high-throughput experiments.

Related Articles

This content was generated with the help of AI and it may contain mistakes